Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK822.00.

European healthcare stocks tumble as Trump prepares new tariffs, with pharmaceutical firms bracing for economic fallout and market uncertainty.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Big Pharma has aimed some choice words at European countries in recent weeks, including calling the UK “uninvestable” and ...

Multinational corporations are expanding the availability of drugs in the hospital segment in anticipation of growing demand ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

Discussions at the Advanced Technologies & Treatments for Diabetes meeting covered CGM use in non–insulin-treated people with ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...